Dynamics of Minimal Residual Disease in Neuroblastoma Patients

Suguru Uemura, Toshiaki Ishida, Khin Kyae Mon Thwin, Nobuyuki Yamamoto, Akihiro Tamura, Kenji Kishimoto, Daiichiro Hasegawa, Yoshiyuki Kosaka, Nanako Nino, Kyaw San Lin, Satoru Takafuji, Takeshi Mori, Kazumoto Iijima, Noriyuki Nishimura, Suguru Uemura, Toshiaki Ishida, Khin Kyae Mon Thwin, Nobuyuki Yamamoto, Akihiro Tamura, Kenji Kishimoto, Daiichiro Hasegawa, Yoshiyuki Kosaka, Nanako Nino, Kyaw San Lin, Satoru Takafuji, Takeshi Mori, Kazumoto Iijima, Noriyuki Nishimura

Abstract

Neuroblastoma is a common extracranial solid tumor of neural crest (NC) origin that accounts for up to 15% of all pediatric cancer deaths. The disease arises from a transient population of NC cells that undergo an epithelial-mesenchymal transition (EMT) and generate diverse cell-types and tissues. Patients with neuroblastoma are characterized by their extreme heterogeneity ranging from spontaneous regression to malignant progression. More than half of newly diagnosed patients present highly metastatic tumors and are stratified into a high-risk group with dismal outcome. As many as 20% of high-risk patients have residual disease that is refractory or progressive during induction chemotherapy. Although a majority of high-risk patients achieve remission, larger part of those patients has minimal residual disease (MRD) that causes relapse even after additional consolidation therapy. MRD is composed of drug-resistant tumor cells and dynamically presented as cancer stem cells (CSCs) in residual tumors, circulating tumor cells (CTCs) in peripheral blood (PB), and disseminated tumor cells (DTCs) in bone marrow (BM) and other metastatic sites. EMT appears to be a key mechanism for cancer cells to acquire MRD phenotypes and malignant aggressiveness. Due to the restricted availability of residual tumors, PB and BM have been used to isolate and analyze CTCs and DTCs to evaluate MRD in cancer patients. In addition, recent technical advances make it possible to use circulating tumor DNA (ctDNA) shed from tumor cells into PB for MRD evaluation. Because MRD can be detected by tumor-specific antigens, genetic or epigenetic changes, and mRNAs, numerous assays using different methods and samples have been reported to detect MRD in cancer patients. In contrast to the tumor-specific gene-rearrangement-positive acute lymphoblastic leukemia (ALL) and the oncogenic fusion-gene-positive chronic myelogenous leukemia (CML) and several solid tumors, the clinical significance of MRD remains to be established in neuroblastoma. Given the extreme heterogeneity of neuroblastoma, dynamics of MRD in neuroblastoma patients will hold a key to the clinical validation. In this review, we summarize the biology and detection methods of cancer MRD in general and evaluate the available assays and clinical significance of neuroblastoma MRD to clarify its dynamics in neuroblastoma patients.

Keywords: cancer stem cell (CSC); circulating tumor DNA (ctDNA); circulating tumor cell (CTC); disseminating tumor cell (DTC); epithelial-mesenchymal transition (EMT); minimal residual disease (MRD); neuroblastoma.

Figures

Figure 1
Figure 1
MRD in neuroblastoma. MRD, minimal residual disease; CSC, cancer stem cell; EMT, epithelial-mesenchymal transition.
Figure 2
Figure 2
Dynamics of MRD. MRD, minimal residual disease; CSC, cancer stem cell; CTC, circulating tumor cell; DTC, disseminating tumor cell; ctDNA, circulating tumor DNA; EMT, epithelial-mesenchymal transition.
Figure 3
Figure 3
EMT program in tumor progression. EMT, epithelial-mesenchymal transition; MET, mesenchymal-epithelial transition; CSC, cancer stem cell.
Figure 4
Figure 4
MRD detection methods. MRD, minimal residual disease; CSC, cancer stem cell; CTC, circulating tumor cell; DTC, disseminating tumor cell; ctDNA, circulating tumor DNA; PB, peripheral blood; PBSC, peripheral blood stem cell; BM, bone marrow; IC, immunocytology; FCM, flow cytometry; PCR, polymerase chain reaction; aCGH, array comparative genomic hybridization; MPS, massively paralleled sequencing; RT-PCR, reverse transcriptase-PCR.
Figure 5
Figure 5
Sampling from neuroblastoma patients. MRD, minimal residual disease; PB, peripheral blood; PBSC, peripheral blood stem cell; BM, bone marrow; IC, immunocytology.

References

    1. Tomolonis JA, Agarwal S, Shohet JM. Neuroblastoma pathogenesis: deregulation of embryonic neural crest development. Cell Tissue Res. (2018) 372:245–62. 10.1007/s00441-017-2747-0
    1. Delloye-Bourgeois C, Castellani V. Hijacking of embryonic programs by neural crest-derived neuroblastoma: from physiological migration to metastatic dissemination. Front Mol Neurosci. (2019) 12:366. 10.3389/fnmol.2019.00052
    1. Dongre A, Weinberg RA. New insights into the mechanisms of epithelial–mesenchymal transition and implications for cancer. Nat Rev Mol Cell Biol. (2019) 20:69–84. 10.1038/s41580-018-0080-4
    1. Shibue T, Weinberg RA. EMT, CSCs, and drug resistance: the mechanistic link and clinical implications. Nat Rev Clin Oncol. (2017) 14:611–629. 10.1038/nrclinonc.2017.44
    1. Tanno B, Sesti F, Cesi V, Bossi G, Ferrari-Amorotti G, Bussolari R, et al. . Expression of Slug is regulated by c-Myb and is required for invasion and bone marrow homing of cancer cells of different origin. J Biol Chem. (2010) 285:29434–45. 10.1074/jbc.M109.089045
    1. Ferronha T, Rabadán MA, Gil-Guiñon E, Le Dréau G, de Torres C, Martí E. LMO4 is an essential cofactor in the Snail2-mediated epithelial-to-mesenchymal transition of neuroblastoma and neural crest cells. J Neurosci. (2013) 33:2773–83. 10.1523/JNEUROSCI.4511-12.2013
    1. Li D, Mei H, Qi M, Yang D, Zhao X, Xiang X, et al. . FOXD3 is a novel tumor suppressor that affects growth, invasion, metastasis and angiogenesis of neuroblastoma. Oncotarget. (2013) 4:2021–44. 10.18632/oncotarget.1579
    1. Vo KT, Matthay KK, Neuhaus J, London WB, Hero B, Ambros PF, et al. . Clinical, biologic, and prognostic differences on the basis of primary tumor site in neuroblastoma: a report from the international neuroblastoma risk group project. J Clin Oncol. (2014) 32:3169–76. 10.1200/JCO.2014.56.1621
    1. Boeva V, Louis-Brennetot C, Peltier A, Durand S, Pierre-Eugène C, Raynal V, et al. . Heterogeneity of neuroblastoma cell identity defined by transcriptional circuitries. Nat Genet. (2017) 49:1408–13. 10.1038/ng.3921
    1. van Groningen T, Koster J, Valentijn LJ, Zwijnenburg DA, Akogul N, Hasselt NE, et al. . Neuroblastoma is composed of two super-enhancer-associated differentiation states. Nat Genet. (2017) 49:1261–6. 10.1038/ng.3899
    1. Brodeur GM. Neuroblastoma: biological insights into a clinical enigma. Nat Rev Cancer. (2003) 3:203–16. 10.1038/nrc1014
    1. Nakagawara A, Li Y, Izumi H, Muramori K, Inada H, Nishi M. Neuroblastoma. Jpn J Clin Oncol. (2018) 48:214–41. 10.1093/jjco/hyx176
    1. Maris JM, Hogarty MD, Bagatell R, Cohn SL. Neuroblastoma. Lancet. (2007) 369:2106–20. 10.1016/S0140-6736(07)60983-0
    1. Maris JM. Recent advances in neuroblastoma. N Engl J Med. (2010) 362:2202–11. 10.1056/NEJMra0804577
    1. Pinto NR, Applebaum MA, Volchenboum SL, Matthay KK, London WB, Ambros PF, et al. . Advances in risk classification and treatment strategies for neuroblastoma. J Clin Oncol. (2015) 33:3008–17. 10.1200/JCO.2014.59.4648
    1. Park JR, Kreissman SG, London WB, Naranjo A, Cohn SL, Hogarty MD, et al. A phase III randomized clinical trial (RCT) of tandem myeloablative autologous stem cell transplant (ASCT) using peripheral blood stem cell (PBSC) as consolidation therapy for high-risk neuroblastoma (HR-NB): A Children's Oncology Group (COG) study. J Clin Oncol. (2016) 34:LBA3 10.1200/JCO.2016.34.18_suppl.LBA3
    1. Tolbert VP, Matthay KK. Neuroblastoma: clinical and biological approach to risk stratification and treatment. Cell Tissue Res. (2018) 372:195–209. 10.1007/s00441-018-2821-2
    1. Wan L, Pantel K, Kang Y. Tumor metastasis: moving new biological insights into the clinic. Nat Med. (2013) 19:1450–64. 10.1038/nm.3391
    1. Turajlic S, Swanton C. Metastasis as an evolutionary process. Science. (2016) 352:169–75. 10.1126/science.aaf2784
    1. Burchill SA, Selby PJ. Molecular detection of low-level disease in patients with cancer. J Pathol. (2000) 190:6–14. 10.1002/(SICI)1096-9896(200001)190:1<6::AID-PATH486>;2-M
    1. Pantel K, Brakenhoff RH. Dissecting the metastatic cascade. Nat Rev Cancer. (2004) 4:448–56. 10.1038/nrc1370
    1. Mordant P, Loriot Y, Lahon B, Castier Y, Lesèche G, Soria J-C, et al. Minimal residual disease in solid neoplasia: new frontier or red-herring? Cancer Treat Rev. (2012) 38:101–10. 10.1016/j.ctrv.2011.04.014
    1. Pantel K, Alix-Panabières C. Bone marrow as a reservoir for disseminated tumor cells: a special source for liquid biopsy in cancer patients. Bonekey Rep. (2014) 3:584. 10.1038/bonekey.2014.79
    1. Pantel K, Speicher MR. The biology of circulating tumor cells. Oncogene. (2016) 35:1216–24. 10.1038/onc.2015.192
    1. Wang H, Stoecklein NH, Lin PP, Gires O. Circulating and disseminated tumor cells: diagnostic tools and therapeutic targets in motion. Oncotarget. (2017) 8:1884–912. 10.18632/oncotarget.12242
    1. Alix-Panabières C, Schwarzenbach H, Pantel K. Circulating tumor cells and circulating tumor DNA. Annu Rev Med. (2012) 63:199–215. 10.1146/annurev-med-062310-094219
    1. Sumbal S, Javed A, Afroze B, Zulfiqar HF, Javed F, Noreen S, et al. . Circulating tumor DNA in blood: future genomic biomarkers for cancer detection. Exp Hematol. (2018) 65:17–28. 10.1016/j.exphem.2018.06.003
    1. Heppner GH. Tumor heterogeneity. Cancer Res. (1984) 44:2259–65.
    1. Welch DR. Tumor heterogeneity—A “contemporary concept” founded on historical insights and predictions. Cancer Res. (2016) 76:4–6. 10.1158/0008-5472.CAN-15-3024
    1. Burrell RA, McGranahan N, Bartek J, Swanton C. The causes and consequences of genetic heterogeneity in cancer evolution. Nature. (2013) 501:338–45. 10.1038/nature12625
    1. Meacham CE, Morrison SJ. Tumor heterogeneity and cancer cell plasticity. Nature. (2013) 501:328–37. 10.1038/nature12624
    1. De Sousa E, Melo F, Vermeulen L, Fessler E, Medema JP. Cancer heterogeneity-a multifaceted view. EMBO Rep. (2013) 14:686–695. 10.1038/embor.2013.92
    1. Jordan CT, Guzman ML, Noble M. Cancer stem cells. N Engl J Med. (2006) 355:1253–61. 10.1056/NEJMra061808
    1. Vermeulen L, de Sousa e, Melo F, Richel DJ, Medema JP. The developing cancer stem-cell model: clinical challenges and opportunities. Lancet Oncol. (2012) 13:e83–9. 10.1016/S1470-2045(11)70257-1
    1. Visvader JE, Lindeman GJ. Cancer stem cells in solid tumors: accumulating evidence and unresolved questions. Nat Rev Cancer. (2008) 8:755–68. 10.1038/nrc2499
    1. Bedard PL, Hansen AR, Ratain MJ, Siu LL. Tumour heterogeneity in the clinic. Nature. (2013) 501:355–64. 10.1038/nature12627
    1. Mani SA, Guo W, Liao M-J, Eaton EN, Ayyanan A, Zhou AY, et al. . The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell. (2008) 133:704–15. 10.1016/j.cell.2008.03.027
    1. Nieto MA. Epithelial plasticity: a common theme in embryonic and cancer cells. Science. (2013) 342:1234850. 10.1126/science.1234850
    1. Ye X, Weinberg RA. Epithelial-mesenchymal plasticity: a central regulator of cancer progression. Trends Cell Biol. (2015) 25:675–86. 10.1016/j.tcb.2015.07.012
    1. Pastushenko I, Brisebarre A, Sifrim A, Fioramonti M, Revenco T, Boumahdi S, et al. . Identification of the tumour transition states occurring during EMT. Nature. (2018) 556:463–8. 10.1038/s41586-018-0040-3
    1. Massagué J, Obenauf AC. Metastatic colonization by circulating tumour cells. Nature. (2016) 529:298–306. 10.1038/nature17038
    1. Micalizzi DS, Maheswaran S, Haber DA. A conduit to metastasis: circulating tumor cell biology. Genes Dev. (2017) 31:1827–40. 10.1101/gad.305805.117
    1. Baccelli I, Schneeweiss A, Riethdorf S, Stenzinger A, Schillert A, Vogel V, et al. . Identification of a population of blood circulating tumor cells from breast cancer patients that initiates metastasis in a xenograft assay. Nat Biotechnol. (2013) 31:539–544. 10.1038/nbt.2576
    1. Hodgkinson CL, Morrow CJ, Li Y, Metcalf RL, Rothwell DG, Trapani F, et al. . Tumorigenicity and genetic profiling of circulating tumor cells in small-cell lung cancer. Nat Med. (2014) 20:897–903. 10.1038/nm.3600
    1. Yu M, Bardia A, Wittner BS, Stott SL, Smas ME, Ting DT, et al. . Circulating breast tumor cells exhibit dynamic changes in epithelial and mesenchymal composition. Science. (2013) 339:580–4. 10.1126/science.1228522
    1. Chang L, Graham PH, Hao J, Ni J, Bucci J, Cozzi PJ, et al. . Acquisition of epithelial–mesenchymal transition and cancer stem cell phenotypes is associated with activation of the PI3K/Akt/mTOR pathway in prostate cancer radioresistance. Cell Death Dis. (2013) 4:e875. 10.1038/cddis.2013.407
    1. Aceto N, Bardia A, Miyamoto DT, Donaldson MC, Wittner BS, Spencer JA, et al. . Circulating tumor cell clusters are oligoclonal precursors of breast cancer metastasis. Cell. (2014) 158:1110–22. 10.1016/j.cell.2014.07.013
    1. Joosse SA, Gorges TM, Pantel K. Biology, detection, and clinical implications of circulating tumor cells. EMBO Mol Med. (2015) 7:1–11. 10.15252/emmm.201303698
    1. Mitra A, Mishra L, Li S. EMT, CTCs and CSCs in tumor relapse and drug-resistance. Oncotarget. (2015) 6:10697–711. 10.18632/oncotarget.4037
    1. Uhr JW, Pantel K. Controversies in clinical cancer dormancy. Proc Natl Acad Sci USA. (2011) 108:12396–400. 10.1073/pnas.1106613108
    1. Riethdorf S, Pantel K. Disseminated tumor cells in bone marrow and circulating tumor cells in blood of breast cancer patients: current state of detection and characterization. Pathobiology. (2008) 75:140–8. 10.1159/000123852
    1. Hosch S, Kraus J, Scheunemann P, Izbicki JR, Schneider C, Schumacher U, et al. . Malignant potential and cytogenetic characteristics of occult disseminated tumor cells in esophageal cancer. Cancer Res. (2000) 60:6836–40.
    1. Aguirre-Ghiso JA. Models, mechanisms and clinical evidence for cancer dormancy. Nat Rev Cancer. (2007) 7:834–46. 10.1038/nrc2256
    1. Yeh AC, Ramaswamy S. Mechanisms of cancer cell dormancy—another hallmark of cancer? Cancer Res. (2015) 75:5014–22. 10.1158/0008-5472.CAN-15-1370
    1. Dittmer J. Mechanisms governing metastatic dormancy in breast cancer. Semin Cancer Biol. (2017) 44:72–82. 10.1016/j.semcancer.2017.03.006
    1. Heitzer E, Ulz P, Geigl JB. Circulating tumor DNA as a liquid biopsy for cancer. Clin Chem. (2015) 61:112–23. 10.1373/clinchem.2014.222679
    1. Jung K, Fleischhacker M, Rabien A. Cell-free DNA in the blood as a solid tumor biomarker—a critical appraisal of the literature. Clin Chim Acta. (2010) 411:1611–24. 10.1016/j.cca.2010.07.032
    1. Schwarzenbach H, Hoon DSB, Pantel K. Cell-free nucleic acids as biomarkers in cancer patients. Nat Rev Cancer. (2011) 11:426–37. 10.1038/nrc3066
    1. Moss TJ, Reynolds CP, Sather HN, Romansky SG, Hammond GD, Seeger RC. Prognostic value of immunocytologic detection of bone marrow metastases in neuroblastoma. N Engl J Med. (1991) 324:219–26. 10.1056/NEJM199101243240403
    1. Cheung NK, Heller G, Kushner BH, Liu C, Cheung IY. Detection of metastatic neuroblastoma in bone marrow: when is routine marrow histology insensitive? J Clin Oncol. (1997) 15:2807–17. 10.1200/JCO.1997.15.8.2807
    1. Komada Y, Zhang XL, Zhou YW, Inaba H, Deguchi T, Azuma E, et al. . Flow cytometric analysis of peripheral blood and bone marrow for tumor cells in patients with neuroblastoma. Cancer. (1998) 82:591–9.
    1. Seeger RC, Reynolds CP, Gallego R, Stram DO, Gerbing RB, Matthay KK. Quantitative tumor cell content of bone marrow and blood as a predictor of outcome in stage IV neuroblastoma: a Children's Cancer Group Study. J Clin Oncol. (2000) 18:4067–76. 10.1200/JCO.2000.18.24.4067
    1. Swerts K, Ambros PF, Brouzes C, Navarro JMF, Gross N, Rampling D, et al. . Standardization of the immunocytochemical detection of neuroblastoma cells in bone marrow. J Histochem Cytochem. (2005) 53:1433–40. 10.1369/jhc.5C6661.2005
    1. Swerts K, De Moerloose B, Dhooge C, Brichard B, Benoit Y, Laureys G, et al. . Detection of residual neuroblastoma cells in bone marrow: comparison of flow cytometry with immunocytochemistry. Cytometry B Clin Cytom. (2004) 61:9–19. 10.1002/cyto.b.20019
    1. Beiske K, Ambros PF, Burchill SA, Cheung IY, Swerts K. Detecting minimal residual disease in neuroblastoma patients-the present state of the art. Cancer Lett. (2005) 228:229–40. 10.1016/j.canlet.2005.02.053
    1. Beiske K, Burchill SA, Cheung IY, Hiyama E, Seeger RC, Cohn SL, et al. . Consensus criteria for sensitive detection of minimal neuroblastoma cells in bone marrow, blood and stem cell preparations by immunocytology and QRT-PCR: recommendations by the international neuroblastoma risk group task force. Br J Cancer. (2009) 100:1627–37. 10.1038/sj.bjc.6605029
    1. Wang L, Wheeler DA. Genomic sequencing for cancer diagnosis and therapy. Annu Rev Med. (2014) 65:33–48. 10.1146/annurev-med-120811-171056
    1. van der Velden VHJ, Panzer-Grümayer ER, Cazzaniga G, Flohr T, Sutton R, Schrauder A, et al. . Optimization of PCR-based minimal residual disease diagnostics for childhood acute lymphoblastic leukemia in a multi-center setting. Leukemia. (2007) 21:706–13. 10.1038/sj.leu.2404535
    1. van der Velden VHJ, Cazzaniga G, Schrauder A, Hancock J, Bader P, Panzer-Grümayer ER, et al. . Analysis of minimal residual disease by Ig/TCR gene rearrangements: guidelines for interpretation of real-time quantitative PCR data. Leukemia. (2007) 21:604–11. 10.1038/sj.leu.2404586
    1. Flohr T, Schrauder A, Cazzaniga G, Panzer-Grümayer R, van der Velden V, Fischer S, et al. . Minimal residual disease-directed risk stratification using real-time quantitative PCR analysis of immunoglobulin and T-cell receptor gene rearrangements in the international multicenter trial AIEOP-BFM ALL 2000 for childhood acute lymphoblastic leukemia. Leukemia. (2008) 22:771–82. 10.1038/leu.2008.5
    1. Berry DA, Zhou S, Higley H, Mukundan L, Fu S, Reaman GH, et al. . Association of minimal residual disease with clinical outcome in pediatric and adult acute lymphoblastic leukemia: a meta-analysis. JAMA Oncol. (2017) 3:e170580. 10.1001/jamaoncol.2017.0580
    1. Huang D, Sun W, Zhou Y, Li P, Chen F, Chen H, et al. . Mutations of key driver genes in colorectal cancer progression and metastasis. Cancer Metastasis Rev. (2018) 37:173–87. 10.1007/s10555-017-9726-5
    1. Leary RJ, Kinde I, Diehl F, Schmidt K, Clouser C, Duncan C, et al. . Development of personalized tumor biomarkers using massively parallel sequencing. Sci Transl Med. (2010) 2:20ra14. 10.1126/scitranslmed.3000702
    1. Hughes T, Deininger M, Hochhaus A, Branford S, Radich J, Kaeda J, et al. . Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results. Blood. (2006) 108:28–37. 10.1182/blood-2006-01-0092
    1. Kantarjian H, Shah NP, Hochhaus A, Cortes J, Shah S, Ayala M, et al. . Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med. (2010) 362:2260–70. 10.1056/NEJMoa1002315
    1. Smith B, Selby P, Southgate J, Pittman K, Bradley C, Blair GE. Detection of melanoma cells in peripheral blood by means of reverse transcriptase and polymerase chain reaction. Lancet. (1991) 338:1227–9.
    1. Carey PJ, Thomas L, Buckle G, Reid MM. Immunocytochemical examination of bone marrow in disseminated neuroblastoma. J Clin Pathol. (1990) 43:9–12. 10.1136/jcp.43.1.9
    1. Moss TJ, Sanders DG. Detection of neuroblastoma cells in blood. J Clin Oncol. (1990) 8:736–40. 10.1200/JCO.1990.8.4.736
    1. Moss TJ, Cairo M, Santana VM, Weinthal J, Hurvitz C, Bostrom B. Clonogenicity of circulating neuroblastoma cells: implications regarding peripheral blood stem cell transplantation. Blood. (1994) 83:3085–9. 10.1182/pgash-83-10-3085
    1. Dhillon A, Roder J, Leathem A. Neurone specific enolase: an aid to the diagnosis of melanoma and neuroblastoma. Histopathology. (1982) 6:81–92. 10.1111/j.1365-2559.1982.tb02704.x
    1. Gould VE, Wiedenmann B, Lee I, Schwechheimer K, Dockhorn-Dworniczak B, Radosevich JA, et al. . Synaptophysin expression in neuroendocrine neoplasms as determined by immunocytochemistry. Am J Pathol. (1987) 126:243–57.
    1. Thomas JO, Nijjar J, Turley H, Micklem K, Gatter KC. NB84: a new monoclonal antibody for the recognition of neuroblastoma in routinely processed material. J Pathol. (1991) 163:69–75. 10.1002/path.1711630112
    1. Helman LJ, Gazdar AF, Park JG, Cohen PS, Cotelingam JD, Israel MA. Chromogranin A expression in normal and malignant human tissues. J Clin Invest. (1988) 82:686–90. 10.1172/JCI113648
    1. Goldman A, Vivian G, Gordon I, Pritchard J, Kemshead J. Immunolocalization of neuroblastoma using radiolabeled monoclonal antibody UJ13A. J Pediatr. (1984) 105:252–6. 10.1016/S0022-3476(84)80122-5
    1. Patel K, Moore SE, Dickson G, Rossell RJ, Beverley PC, Kemshead JT, et al. . Neural cell adhesion molecule (NCAM) is the antigen recognized by monoclonal antibodies of similar specificity in small-cell lung carcinoma and neuroblastoma. Int J Cancer. (1989) 44:573–8. 10.1002/ijc.2910440402
    1. Sugimoto T, Sawada T, Matsumura T, Kemshead JT, Horii Y, Saida T, et al. . Diagnosis of neuroblastoma metastasis in bone marrow with a panel of monoclonal antibodies. Med Pediatr Oncol. (1988) 16:190–6. 10.1002/mpo.2950160308
    1. Cheung NK, Von Hoff DD, Strandjord SE, Coccia PF. Detection of neuroblastoma cells in bone marrow using GD2 specific monoclonal antibodies. J Clin Oncol. (1986) 4:363–9. 10.1200/JCO.1986.4.3.363
    1. Sariola H, Terävä H, Rapola J, Saarinen UM. Cell-surface ganglioside GD2 in the immunohistochemical detection and differential diagnosis of neuroblastoma. Am J Clin Pathol. (1991) 96:248–52.
    1. Ferreira-Facio CS, Milito C, Botafogo V, Fontana M, Thiago LS, Oliveira E, et al. . Contribution of multiparameter flow cytometry immunophenotyping to the diagnostic screening and classification of pediatric cancer. PLoS ONE. (2013) 8:e55534. 10.1371/journal.pone.0055534
    1. Bryson GJ, Lear D, Williamson R, Wong RCW. Detection of the CD56+/CD45- immunophenotype by flow cytometry in neuroendocrine malignancies. J Clin Pathol. (2002) 55:535–7. 10.1136/jcp.55.7.535
    1. Nagai J, Ishida Y, Koga N, Tanaka Y, Ohnuma K, Toyoda Y, et al. . A new sensitive and specific combination of CD81/CD56/CD45 monoclonal antibodies for detecting circulating neuroblastoma cells in peripheral blood using flow cytometry. J Pediatr Hematol Oncol. (2000) 22:20–6.
    1. Warzynski MJ, Graham DM, Axtell RA, Higgins JV, Hammers YA. Flow cytometric immunophenotyping test for staging/monitoring neuroblastoma patients. Cytometry. (2002) 50:298–304. 10.1002/cyto.10159
    1. Bozzi F, Gambirasio F, Luksch R, Collini P, Brando B, Fossati-Bellani F. Detecting CD56+/NB84+/CD45- immunophenotype in the bone marrow of patients with metastatic neuroblastoma using flow cytometry. Anticancer Res. (2006) 26:3281–7.
    1. Popov A, Druy A, Shorikov E, Verzhbitskaya T, Solodovnikov A, Saveliev L, et al. . Prognostic value of initial bone marrow disease detection by multiparameter flow cytometry in children with neuroblastoma. J Cancer Res Clin Oncol. (2019) 145:535–42. 10.1007/s00432-018-02831-w
    1. Yáñez Y, Grau E, Oltra S, Cañete A, Martínez F, Orellana C, et al. . Minimal disease detection in peripheral blood and bone marrow from patients with non-metastatic neuroblastoma. J Cancer Res Clin Oncol. (2011) 137:1263–72. 10.1007/s00432-011-0997-x
    1. Stutterheim J, Zappeij-Kannegieter L, Versteeg R, Caron HN, van der Schoot CE, Tytgat GAM. The prognostic value of fast molecular response of marrow disease in patients aged over 1 year with stage 4 neuroblastoma. Eur J Cancer. (2011) 47:1193–202. 10.1016/j.ejca.2011.02.003
    1. Chambon F, Tchirkov A, Pereira B, Rochette E, Deméocq F, Kanold J. Molecular assessment of minimal residual disease in PBSC harvests provides prognostic information in neuroblastoma. Pediatr Blood Cancer. (2013) 60:E109–12. 10.1002/pbc.24538
    1. Viprey VF, Gregory WM, Corrias MV, Tchirkov A, Swerts K, Vicha A, et al. . Neuroblastoma mRNAs predict outcome in children with stage 4 neuroblastoma: a European HR-NBL1/SIOPEN study. J Clin Oncol. (2014) 32:1074–83. 10.1200/JCO.2013.53.3604
    1. van Wezel EM, Decarolis B, Stutterheim J, Zappeij-Kannegieter L, Berthold F, Schumacher Kuckelkorn R, et al. . Neuroblastoma messenger RNA is frequently detected in bone marrow at diagnosis of localised neuroblastoma patients. Eur J Cancer. (2016) 54:149–58. 10.1016/j.ejca.2015.11.007
    1. Yáñez Y, Hervás D, Grau E, Oltra S, Pérez G, Palanca S, et al. . TH and DCX mRNAs in peripheral blood and bone marrow predict outcome in metastatic neuroblastoma patients. J Cancer Res Clin Oncol. (2016) 142:573–80. 10.1007/s00432-015-2054-7
    1. Marachelian A, Villablanca JG, Liu CW, Liu B, Goodarzian F, Lai HA, et al. . Expression of five neuroblastoma genes in bone marrow or blood of patients with relapsed/refractory neuroblastoma provides a new biomarker for disease and prognosis. Clin Cancer Res. (2017) 23:5374–83. 10.1158/1078-0432.CCR-16-2647
    1. Bosse KR, Maris JM. Advances in the translational genomics of neuroblastoma: from improving risk stratification and revealing novel biology to identifying actionable genomic alterations. Cancer. (2016) 122:20–33. 10.1002/cncr.29706
    1. Stutterheim J, Ichou FA, den Ouden E, Versteeg R, Caron HN, Tytgat GAM, et al. . Methylated RASSF1a is the first specific DNA marker for minimal residual disease testing in neuroblastoma. Clin Cancer Res. (2012) 18:808–14. 10.1158/1078-0432.CCR-11-0849
    1. van Wezel EM, Zwijnenburg D, Zappeij-Kannegieter L, Bus E, van Noesel MM, Molenaar JJ, et al. . Whole-genome sequencing identifies patient-specific DNA minimal residual disease markers in neuroblastoma. J Mol Diagn. (2015) 17:43–52. 10.1016/j.jmoldx.2014.09.005
    1. Chicard M, Colmet Daage L, Clement N, Danzon A, Bohec M, Bernard V, et al. . Whole-exome sequencing of cell-free DNA reveals temporo-spatial heterogeneity and identifies treatment-resistant clones in neuroblastoma. Clin Cancer Res. (2018) 24:939–49. 10.1158/1078-0432.CCR-17-1586
    1. Cheung IY, Cheung NK. Quantitation of marrow disease in neuroblastoma by real-time reverse transcription-PCR. Clin Cancer Res. (2001) 7:1698–705.
    1. Cheung IY, Feng Y, Vickers A, Gerald W, Cheung N-KV. Cyclin D1, a novel molecular marker of minimal residual disease, in metastatic neuroblastoma. J Mol Diagn. (2007) 9:237–241. 10.2353/jmoldx.2007.060130
    1. Pagani A, Macri L, Faulknerf LB, Tintori V, Paoli A, Garaventa A, et al. . Detection procedures for neuroblastoma cells metastatic to blood and bone marrow: blinded comparison of chromogranin A heminested reverse transcription polymerase chain reaction to tyrosine hydroxylase nested reverse transcription polymerase chain reaction and to anti-GD2 immunocytology. Diagn Mol Pathol. (2002) 11:98–106.
    1. Stutterheim J, Gerritsen A, Zappeij-Kannegieter L, Yalcin B, Dee R, van Noesel MM, et al. . Detecting minimal residual disease in neuroblastoma: the superiority of a panel of real-time quantitative PCR markers. Clin Chem. (2009) 55:1316–26. 10.1373/clinchem.2008.117945
    1. Cheung IY, Feng Y, Gerald W, Cheung N-KV. Exploiting gene expression profiling to identify novel minimal residual disease markers of neuroblastoma. Clin Cancer Res. (2008) 14:7020–7. 10.1158/1078-0432.CCR-08-0541
    1. Kuci Z, Seitz G, Kuci S, Kreyenberg H, Schumm M, Lang P, et al. . Pitfalls in detection of contaminating neuroblastoma cells by tyrosine hydroxylase RT-PCR due to catecholamine-producing hematopoietic cells. Anticancer Res. (2006) 26:2075–80.
    1. Oltra S, Martínez F, Orellana C, Grau E, Fernandez JM, Cañete A, et al. . The doublecortin gene, a new molecular marker to detect minimal residual disease in neuroblastoma. Diagn Mol Pathol. (2005) 14:53–7. 10.1097/01.pas.0000149876.32376.c0
    1. Bozzi F, Luksch R, Collini P, Gambirasio F, Barzanò E, Polastri D, et al. . Molecular detection of dopamine decarboxylase expression by means of reverse transcriptase and polymerase chain reaction in bone marrow and peripheral blood: utility as a tumor marker for neuroblastoma. Diagn Mol Pathol. (2004) 13:135–143.
    1. Swerts K. Potential application of ELAVL4 real-time quantitative reverse transcription-PCR for detection of disseminated neuroblastoma cells. Clin Chem. (2006) 52:438–45. 10.1373/clinchem.2005.059485
    1. Cheung IY, Cheung NK. Molecular detection of GAGE expression in peripheral blood and bone marrow: utility as a tumor marker for neuroblastoma. Clin Cancer Res. (1997) 3:821–6.
    1. Stutterheim J, Gerritsen A, Zappeij-Kannegieter L, Kleijn I, Dee R, Hooft L, et al. . PHOX2B is a novel and specific marker for minimal residual disease testing in neuroblastoma. J Clin Oncol. (2008) 26:5443–9. 10.1200/JCO.2007.13.6531
    1. Cheung IY, Vickers A, Cheung N-KV. Sialyltransferase STX (ST8SiaII): a novel molecular marker of metastatic neuroblastoma. Int J Cancer. (2006) 119:152–6. 10.1002/ijc.21789
    1. Naito H, Kuzumaki N, Uchino J, Kobayashi R, Shikano T, Ishikawa Y, et al. . Detection of tyrosine hydroxylase mRNA and minimal neuroblastoma cells by the reverse transcription-polymerase chain reaction. Eur J Cancer. (1991) 27:762–5.
    1. Burchill SA, Bradbury FM, Smith B, Lewis IJ, Selby P. Neuroblastoma cell detection by reverse transcriptase-polymerase chain reaction (RT-PCR) for tyrosine hydroxylase mRNA. Int J Cancer. (1994) 57:671–5. 10.1002/ijc.2910570510
    1. Wang Y, Einhorn P, Triche TJ, Seeger RC, Reynolds CP. Expression of protein gene product 9.5 and tyrosine hydroxylase in childhood small round cell tumors. Clin Cancer Res. (2000) 6:551–8.
    1. Viprey VF, Lastowska MA, Corrias MV, Swerts K, Jackson MS, Burchill SA. Minimal disease monitoring by QRT-PCR: guidelines for identification and systematic validation of molecular markers prior to evaluation in prospective clinical trials. J Pathol. (2008) 216:245–52. 10.1002/path.2406
    1. Grèze V, Brugnon F, Chambon F, Halle P, Canis M, Amiot C, et al. . Highly sensitive assessment of neuroblastoma minimal residual disease in ovarian tissue using RT-qPCR-A strategy for improving the safety of fertility restoration. Pediatr Blood Cancer. (2017) 64:e26287. 10.1002/pbc.26287
    1. Grèze V, Kanold J, Chambon F, Halle P, Gremeau A-S, Rives N, et al. . RT-qPCR for PHOX2B mRNA is a highly specific and sensitive method to assess neuroblastoma minimal residual disease in testicular tissue. Oncol Lett. (2017) 14:860–6. 10.3892/ol.2017.6238
    1. van Wezel EM, Stutterheim J, Vree F, Zappeij-Kannegieter L, Decarolis B, Hero B, et al. . Minimal residual disease detection in autologous stem cell grafts from patients with high risk neuroblastoma. Pediatr Blood Cancer. (2015) 62:1368–73. 10.1002/pbc.25507
    1. Hartomo TB, Kozaki A, Hasegawa D, Pham TVH, Yamamoto N, Saitoh A, et al. . Minimal residual disease monitoring in neuroblastoma patients based on the expression of a set of real-time RT-PCR markers in tumor-initiating cells. Oncol Rep. (2013) 29:1629–36. 10.3892/or.2013.2286
    1. Kreissman SG, Seeger RC, Matthay KK, London WB, Sposto R, Grupp SA, et al. . Purged versus non-purged peripheral blood stem-cell transplantation for high-risk neuroblastoma (COG A3973): a randomised phase 3 trial. Lancet Oncol. (2013) 14:999–1008. 10.1016/S1470-2045(13)70309-7
    1. Träger C, Vernby A, Kullman A, Øra I, Kogner P, Kågedal B. mRNAs of tyrosine hydroxylase and dopa decarboxylase but not of GD2 synthase are specific for neuroblastoma minimal disease and predicts outcome for children with high-risk disease when measured at diagnosis. Int J Cancer. (2008) 123:2849–55. 10.1002/ijc.23846
    1. Kågedal B, Kullman A, Lenner L, Träger C, Kogner P, Farnebäck M. Pterin-dependent tyrosine hydroxylase mRNA is not expressed in human melanocytes or melanoma cells. Pigment Cell Res. (2004) 17:346–51. 10.1111/j.1600-0749.2004.00153.x
    1. Cheung N-KV, Cheung IY, Kushner BH, Ostrovnaya I, Chamberlain E, Kramer K, et al. . Murine anti-GD2 monoclonal antibody 3F8 combined with granulocyte-macrophage colony-stimulating factor and 13-cis-retinoic acid in high-risk patients with stage 4 neuroblastoma in first remission. J Clin Oncol. (2012) 30:3264–70. 10.1200/JCO.2011.41.3807
    1. Cheung N-KV, Ostrovnaya I, Kuk D, Cheung IY. Bone marrow minimal residual disease was an early response marker and a consistent independent predictor of survival after anti-GD2 immunotherapy. J Clin Oncol. (2015) 33:755–63. 10.1200/JCO.2014.57.6777
    1. Druy AE, Shorikov EV, Tsaur GA, Popov AM, Zaychikov AN, Tuponogov SN, et al. Prospective investigation of applicability and the prognostic significance of bone marrow involvement in patients with neuroblastoma detected by quantitative reverse transcription PCR. Pediatr Blood Cancer. (2018) 369:e27354 10.1002/pbc.27354
    1. Miyajima Y, Kato K, Numata SI, Kudo K, Horibe K. Detection of neuroblastoma cells in bone marrow and peripheral blood at diagnosis by the reverse transcriptase-polymerase chain reaction for tyrosine hydroxylase mRNA. Cancer. (1995) 75:2757–61.
    1. Morandi F, Corrias MV, Pistoia V. Evaluation of bone marrow as a metastatic site of human neuroblastoma. Ann N Y Acad Sci. (2015) 1335:23–31. 10.1111/nyas.12554
    1. Corrias MV, Haupt R, Carlini B, Cappelli E, Giardino S, Tripodi G, et al. . Multiple target molecular monitoring of bone marrow and peripheral blood samples from patients with localized neuroblastoma and healthy donors. Pediatr Blood Cancer. (2012) 58:43–9. 10.1002/pbc.22960
    1. Burchill SA, Kinsey SE, Picton S, Roberts P, Pinkerton CR, Selby P, et al. . Minimal residual disease at the time of peripheral blood stem cell harvest in patients with advanced neuroblastoma. Med Pediatr Oncol. (2001) 36:213–9. 10.1002/1096-911X(20010101)36:1<213::AID-MPO1052>;2-9
    1. Corrias MV, Haupt R, Carlini B, Parodi S, Rivabella L, Garaventa A, et al. . Peripheral blood stem cell tumor cell contamination and survival of neuroblastoma patients. Clin Cancer Res. (2006) 12:5680–5. 10.1158/1078-0432.CCR-06-0740

Source: PubMed

Sponsorzy i współpracownicy

Warunki medyczne

Interwencje lekowe

3
Subskrybuj